Q-omics provides the consensus-scored TCOF1 profile across patient tissues and cancer cell-line models. TCOF1 expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, TCOF1 is differentially expressed in 16, with the highest sampling consensus in HNSC. Additionally, TCOF1 protein abundance shows 23,758 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight KIRP, HNSC, and GBM as cancer lineages where TCOF1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TCOF1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TCOF1 survival associations across molecular data types. TCOF1 RNA expression shows survival associations in the most cancer types (27), followed by mutation status (7) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TCOF1 RNA expression–survival associations across cancer types. High TCOF1 expression shows unfavorable associations in KIRP, MESO, LIHC, KICH, KIRC and UCEC. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for TCOF1 RNA expression.
This table summarizes TCOF1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 16, while mass-spec protein shows differences in 6. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for TCOF1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TCOF1 shows higher tumor expression in HNSC, KIRC, KIRP, COAD, STAD and BLCA. The HNSC box plot shows higher TCOF1 RNA expression in tumor versus normal tissue (log2 FC = +1.417, t-test p < 0.001).
This table shows molecular features associated with TCOF1 in patient tissues and cancer cell lines. In patient samples, TCOF1 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, TCOF1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Lymphoma, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and LARGE_INTESTINE.
